Nintedanib is a small molecule kinase inhibitor of platelet derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), and fibroblast growth factor receptor (FGFR), which has been approved for the treatment of interstitial lung disease, and which can possibly be used for the treatment of (ILD in) SSc. This evidence concerns the gene PDGFRB and systemic sclerosis.